|
Generics: Global Industry Guide
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
Zahlen und Fakten zur Studie: | 242 seiten | |||||||||
| Inhalt der Studie: |
Datamonitor's Generics: Global Industry Guide is an essential resource for top-level data and analysis covering the Generics industry. It includes detailed data on market size and segmentation, textua.....
Datamonitor's Generics: Global Industry Guide is an essential resource for top-level data and analysis covering the Generics industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis. Scope of the Report * Contains an executive summary and data on value, volume and segmentation * Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies * Incorporates in-depth five forces competitive environment analysis and scorecards * Covers the Global, European and Asia-Pacific markets as well as individual chapters on 5 major markets (France, Germany, Japan, the UK and the US). * Includes a five-year forecast of the industry Highlights The global generics market grew by 5.9% in 2009 to reach a value of $117.7 billion. In 2014, the global generics market is forecast to have a value of $183.2 billion, an increase of 55.7% since 2009. Ethical is the largest segment of the global generics market, accounting for 73.4% of the market's total value. Asia-Pacific accounts for 36.2% of the global generics market value. The level of rivalry within the global generics market is reduced somewhat by strong growth over recent years Why you should buy this report * Spot future trends and developments * Inform your business decisions * Add weight to presentations and marketing materials * Save time carrying out entry-level research Market Definition The generics market consists of all sales of generic drugs for human use at ex-manufacturer prices. Datamonitor defines a generic as an officially-approved copy of an original product whose patent has expired, marketed either as a brand or using the generic name. This definition excludes multi-source copy products that make up much of markets such as India, Spain and Italy. Multi-source copies are drugs still under patent that are offered by manufacturers other than the patent holders. All currency conversions have been calculated at constant 2009 average exchange rates [Studien Infos ausblenden] |
|||||||||||
|
TABLE OF CONTENTS EXECUTIVE SUMMARY 2 INTRODUCTION 18 What is this report about? 18 Who is the target reader? 18 Market definition 18 GLOBAL GENERICS 19 MARKET OVERVIEW 19 MARKET VALUE 20 MARKET SEGMENTATION I 21 MARKET SEGMENTATION II 22 FIVE FORCES ANALYSIS 23 MARKET FORECASTS 31 GENERICS IN ASIA-PACIFIC 32 MARKET OVERVIEW 32 MARKET VALUE 33 MARKET SEGMENTATION I 34 MARKET SEGMENTATION II 35 FIVE FORCES ANALYSIS 36 MARKET FORECASTS 44 GENERICS IN EUROPE 45 MARKET OVERVIEW 45 MARKET VALUE 46 MARKET SEGMENTATION I 47 MARKET SEGMENTATION II 48 FIVE FORCES ANALYSIS 49 MARKET FORECASTS 57 GENERICS IN BELGIUM 58 MARKET OVERVIEW 58 MARKET VALUE 59 MARKET SEGMENTATION I 60 MARKET SEGMENTATION II 61 FIVE FORCES ANALYSIS 62 MARKET FORECASTS 70 MACROECONOMIC INDICATORS 71 GENERICS IN CANADA 73 MARKET OVERVIEW 73 MARKET VALUE 74 MARKET SEGMENTATION I 75 MARKET SEGMENTATION II 76 FIVE FORCES ANALYSIS 77 MARKET FORECASTS 85 MACROECONOMIC INDICATORS 86 GENERICS IN CHINA 88 MARKET OVERVIEW 88 MARKET VALUE 89 MARKET SEGMENTATION I 90 MARKET SEGMENTATION II 91 FIVE FORCES ANALYSIS 92 MACROECONOMIC INDICATORS 100 GENERICS IN FRANCE 102 MARKET OVERVIEW 102 MARKET VALUE 103 MARKET SEGMENTATION I 104 MARKET SEGMENTATION II 105 FIVE FORCES ANALYSIS 106 MARKET FORECASTS 114 MACROECONOMIC INDICATORS 115 GENERICS IN GERMANY 117 MARKET OVERVIEW 117 MARKET VALUE 118 MARKET SEGMENTATION I 119 MARKET SEGMENTATION II 120 FIVE FORCES ANALYSIS 121 MARKET FORECASTS 129 MACROECONOMIC INDICATORS 130 GENERICS IN ITALY 132 MARKET OVERVIEW 132 MARKET VALUE 133 MARKET SEGMENTATION I 134 MARKET SEGMENTATION II 135 FIVE FORCES ANALYSIS 136 MARKET FORECASTS 144 MACROECONOMIC INDICATORS 145 GENERICS IN JAPAN 147 MARKET OVERVIEW 147 MARKET VALUE 148 MARKET SEGMENTATION I 149 MARKET SEGMENTATION II 150 FIVE FORCES ANALYSIS 151 MARKET FORECASTS 159 MACROECONOMIC INDICATORS 160 GENERICS IN THE NETHERLANDS 162 MARKET OVERVIEW 162 MARKET VALUE 163 MARKET SEGMENTATION I 164 MARKET SEGMENTATION II 165 FIVE FORCES ANALYSIS 166 MARKET FORECASTS 174 MACROECONOMIC INDICATORS 175 GENERICS IN SPAIN 177 MARKET OVERVIEW 177 MARKET VALUE 178 MARKET SEGMENTATION I 179 MARKET SEGMENTATION II 180 FIVE FORCES ANALYSIS 181 MARKET FORECASTS 189 MACROECONOMIC INDICATORS 190 GENERICS IN THE UNITED KINGDOM 192 MARKET OVERVIEW 192 MARKET VALUE 193 MARKET SEGMENTATION I 194 MARKET SEGMENTATION II 195 FIVE FORCES ANALYSIS 196 MARKET FORECASTS 204 MACROECONOMIC INDICATORS 205 GENERICS IN THE UNITED STATES 207 MARKET OVERVIEW 207 MARKET VALUE 208 MARKET SEGMENTATION I 209 MARKET SEGMENTATION II 210 FIVE FORCES ANALYSIS 211 MARKET FORECASTS 219 MACROECONOMIC INDICATORS 220 COMPANY PROFILES 222 LEADING COMPANIES 222 APPENDIX 241 Data Research Methodology 241 About Datamonitor 242 Disclaimer 242 LIST OF TABLES Table 1: Global generics market value: $ billion, 2005–09 21 Table 2: Global generics market segmentation I:% share, by value, 2009 22 Table 3: Global generics market segmentation II: % share, by value, 2009 23 Table 4: Global generics market value forecast: $ billion, 2009–14 32 Table 5: Asia-Pacific generics market value: $ billion, 2005–09 34 Table 6: Asia-Pacific generics market segmentation I:% share, by value, 2009 35 Table 7: Asia-Pacific generics market segmentation II: % share, by value, 2009 36 Table 8: Asia-Pacific generics market value forecast: $ billion, 2009–14 45 Table 9: Europe generics market value: $ billion, 2005–09 47 Table 10: Europe generics market segmentation I:% share, by value, 2009 48 Table 11: Europe generics market segmentation II: % share, by value, 2009 49 Table 12: Europe generics market value forecast: $ billion, 2009–14 58 Table 13: Belgium generics market value: $ million, 2005–09 60 Table 14: Belgium generics market segmentation I:% share, by value, 2009 61 Table 15: Belgium generics market segmentation II: % share, by value, 2009 62 Table 16: Belgium generics market value forecast: $ million, 2009–14 71 Table 17: Belgium size of population (million), 2005–09 72 Table 18: Belgium gdp (constant 2000 prices, $ billion), 2005–09 72 Table 19: Belgium gdp (current prices, $ billion), 2005–09 72 Table 20: Belgium inflation, 2005–09 73 Table 21: Belgium consumer price index (absolute), 2005–09 73 Table 22: Belgium exchange rate, 2005–09 73 Table 23: Canada generics market value: $ billion, 2005–09 75 Table 24: Canada generics market segmentation I:% share, by value, 2009 76 Table 25: Canada generics market segmentation II: % share, by value, 2009 77 Table 26: Canada generics market value forecast: $ billion, 2009–14 86 Table 27: Canada size of population (million), 2005–09 87 Table 28: Canada gdp (constant 2000 prices, $ billion), 2005–09 87 Table 29: Canada gdp (current prices, $ billion), 2005–09 87 Table 30: Canada inflation, 2005–09 88 Table 31: Canada consumer price index (absolute), 2005–09 88 Table 32: Canada exchange rate, 2005–09 88 Table 33: China generics market value: $ billion, 2005–09 90 Table 34: China generics market segmentation I:% share, by value, 2009 91 Table 35: China generics market segmentation II: % share, by value, 2009 92 Table 36: China size of population (million), 2005–09 101 Table 37: China gdp (constant 2000 prices, $ billion), 2005–09 101 Table 38: China gdp (current prices, $ billion), 2005–09 101 Table 39: China inflation, 2005–09 102 Table 40: China consumer price index (absolute), 2005–09 102 Table 41: China exchange rate, 2005–09 102 Table 42: France generics market value: $ billion, 2005–09 104 Table 43: France generics market segmentation I:% share, by value, 2009 105 Table 44: France generics market segmentation II: % share, by value, 2009 106 Table 45: France generics market value forecast: $ billion, 2009–14 115 Table 46: France size of population (million), 2005–09 116 Table 47: France gdp (constant 2000 prices, $ billion), 2005–09 116 Table 48: France gdp (current prices, $ billion), 2005–09 116 Table 49: France inflation, 2005–09 117 Table 50: France consumer price index (absolute), 2005–09 117 Table 51: France exchange rate, 2005–09 117 Table 52: Germany generics market value: $ billion, 2005–09 119 Table 53: Germany generics market segmentation I:% share, by value, 2009 120 Table 54: Germany generics market segmentation II: % share, by value, 2009 121 Table 55: Germany generics market value forecast: $ billion, 2009–14 130 Table 56: Germany size of population (million), 2005–09 131 Table 57: Germany gdp (constant 2000 prices, $ billion), 2005–09 131 Table 58: Germany gdp (current prices, $ billion), 2005–09 131 Table 59: Germany inflation, 2005–09 132 Table 60: Germany consumer price index (absolute), 2005–09 132 Table 61: Germany exchange rate, 2005–09 132 Table 62: Italy generics market value: $ million, 2005–09 134 Table 63: Italy generics market segmentation I:% share, by value, 2009 135 Table 64: Italy generics market segmentation II: % share, by value, 2009 136 Table 65: Italy generics market value forecast: $ million, 2009–14 145 Table 66: Italy size of population (million), 2005–09 146 Table 67: Italy gdp (constant 2000 prices, $ billion), 2005–09 146 Table 68: Italy gdp (current prices, $ billion), 2005–09 146 Table 69: Italy inflation, 2005–09 147 Table 70: Italy consumer price index (absolute), 2005–09 147 Table 71: Italy exchange rate, 2005–09 147 Table 72: Japan generics market value: $ billion, 2005–09 149 Table 73: Japan generics market segmentation I:% share, by value, 2009 150 Table 74: Japan generics market segmentation II: % share, by value, 2009 151 Table 75: Japan generics market value forecast: $ billion, 2009–14 160 Table 76: Japan size of population (million), 2005–09 161 Table 77: Japan gdp (constant 2000 prices, $ billion), 2005–09 161 Table 78: Japan gdp (current prices, $ billion), 2005–09 161 Table 79: Japan inflation, 2005–09 162 Table 80: Japan consumer price index (absolute), 2005–09 162 Table 81: Japan exchange rate, 2005–09 162 Table 82: Netherlands generics market value: $ million, 2005–09 164 Table 83: Netherlands generics market segmentation I:% share, by value, 2009 165 Table 84: Netherlands generics market segmentation II: % share, by value, 2009 166 Table 85: Netherlands generics market value forecast: $ million, 2009–14 175 Table 86: Netherlands size of population (million), 2005–09 176 Table 87: Netherlands gdp (constant 2000 prices, $ billion), 2005–09 176 Table 88: Netherlands gdp (current prices, $ billion), 2005–09 176 Table 89: Netherlands inflation, 2005–09 177 Table 90: Netherlands consumer price index (absolute), 2005–09 177 Table 91: Netherlands exchange rate, 2005–09 177 Table 92: Spain generics market value: $ billion, 2005–09 179 Table 93: Spain generics market segmentation I:% share, by value, 2009 180 Table 94: Spain generics market segmentation II: % share, by value, 2009 181 Table 95: Spain generics market value forecast: $ billion, 2009–14 190 Table 96: Spain size of population (million), 2005–09 191 Table 97: Spain gdp (constant 2000 prices, $ billion), 2005–09 191 Table 98: Spain gdp (current prices, $ billion), 2005–09 191 Table 99: Spain inflation, 2005–09 192 Table 100: Spain consumer price index (absolute), 2005–09 192 Table 101: Spain exchange rate, 2005–09 192 Table 102: United Kingdom generics market value: $ billion, 2005–09 194 Table 103: United Kingdom generics market segmentation I:% share, by value, 2009 195 Table 104: United Kingdom generics market segmentation II: % share, by value, 2009 196 Table 105: United Kingdom generics market value forecast: $ billion, 2009–14 205 Table 106: United Kingdom size of population (million), 2005–09 206 Table 107: United Kingdom gdp (constant 2000 prices, $ billion), 2005–09 206 Table 108: United Kingdom gdp (current prices, $ billion), 2005–09 206 Table 109: United Kingdom inflation, 2005–09 207 Table 110: United Kingdom consumer price index (absolute), 2005–09 207 Table 111: United Kingdom exchange rate, 2005–09 207 Table 112: United States generics market value: $ billion, 2005–09 209 Table 113: United States generics market segmentation I:% share, by value, 2009 210 Table 114: United States generics market segmentation II: % share, by value, 2009 211 Table 115: United States generics market value forecast: $ billion, 2009–14 220 Table 116: United States size of population (million), 2005–09 221 Table 117: United States gdp (constant 2000 prices, $ billion), 2005–09 221 Table 118: United States gdp (current prices, $ billion), 2005–09 221 Table 119: United States inflation, 2005–09 222 Table 120: United States consumer price index (absolute), 2005–09 222 Table 121: United States exchange rate, 2005–09 222 Table 122: Bayer AG: key facts 223 Table 123: Bayer AG: key financials ($) 226 Table 124: Bayer AG: key financials (€) 226 Table 125: Bayer AG: key financial ratios 227 Table 126: Mylan Laboratories Inc.: key facts 229 Table 127: Mylan Laboratories Inc.: key financials ($) 230 Table 128: Mylan Laboratories Inc.: key financial ratios 230 Table 129: Novartis AG: key facts 233 Table 130: Novartis AG: key financials ($) 234 Table 131: Novartis AG: key financial ratios 235 Table 132: Teva Pharmaceutical Industries: key facts 237 Table 133: Teva Pharmaceutical Industries: key financials ($) 239 Table 134: Teva Pharmaceutical Industries: key financial ratios 240 LIST OF FIGURES Figure 1: Global generics market value: $ billion, 2005–09 21 Figure 2: Global generics market segmentation I:% share, by value, 2009 22 Figure 3: Global generics market segmentation II: % share, by value, 2009 23 Figure 4: Forces driving competition in the global generics market, 2009 24 Figure 5: Drivers of buyer power in the global generics market, 2009 26 Figure 6: Drivers of supplier power in the global generics market, 2009 27 Figure 7: Factors influencing the likelihood of new entrants in the global generics market, 2009 28 Figure 8: Factors influencing the threat of substitutes in the global generics market, 2009 30 Figure 9: Drivers of degree of rivalry in the global generics market, 2009 31 Figure 10: Global generics market value forecast: $ billion, 2009–14 32 Figure 11: Asia-Pacific generics market value: $ billion, 2005–09 34 Figure 12: Asia-Pacific generics market segmentation I:% share, by value, 2009 35 Figure 13: Asia-Pacific generics market segmentation II: % share, by value, 2009 36 Figure 14: Forces driving competition in the generics market in Asia-Pacific, 2009 37 Figure 15: Drivers of buyer power in the generics market in Asia-Pacific, 2009 39 Figure 16: Drivers of supplier power in the generics market in Asia-Pacific, 2009 40 Figure 17: Factors influencing the likelihood of new entrants in the generics market in Asia-Pacific, 2009 41 Figure 18: Factors influencing the threat of substitutes in the generics market in Asia-Pacific, 2009 43 Figure 19: Drivers of degree of rivalry in the generics market in Asia-Pacific, 2009 44 Figure 20: Asia-Pacific generics market value forecast: $ billion, 2009–14 45 Figure 21: Europe generics market value: $ billion, 2005–09 47 Figure 22: Europe generics market segmentation I:% share, by value, 2009 48 Figure 23: Europe generics market segmentation II: % share, by value, 2009 49 Figure 24: Forces driving competition in the generics market in Europe, 2009 50 Figure 25: Drivers of buyer power in the generics market in Europe, 2009 52 Figure 26: Drivers of supplier power in the generics market in Europe, 2009 53 Figure 27: Factors influencing the likelihood of new entrants in the generics market in Europe, 2009 54 Figure 28: Factors influencing the threat of substitutes in the generics market in Europe, 2009 56 Figure 29: Drivers of degree of rivalry in the generics market in Europe, 2009 57 Figure 30: Europe generics market value forecast: $ billion, 2009–14 58 Figure 31: Belgium generics market value: $ million, 2005–09 60 Figure 32: Belgium generics market segmentation I:% share, by value, 2009 61 Figure 33: Belgium generics market segmentation II: % share, by value, 2009 62 Figure 34: Forces driving competition in the generics market in Belgium, 2009 63 Figure 35: Drivers of buyer power in the generics market in Belgium, 2009 65 Figure 36: Drivers of supplier power in the generics market in Belgium, 2009 66 Figure 37: Factors influencing the likelihood of new entrants in the generics market in Belgium, 2009 67 Figure 38: Factors influencing the threat of substitutes in the generics market in Belgium, 2009 69 Figure 39: Drivers of degree of rivalry in the generics market in Belgium, 2009 70 Figure 40: Belgium generics market value forecast: $ million, 2009–14 71 Figure 41: Canada generics market value: $ billion, 2005–09 75 Figure 42: Canada generics market segmentation I:% share, by value, 2009 76 Figure 43: Canada generics market segmentation II: % share, by value, 2009 77 Figure 44: Forces driving competition in the generics market in Canada, 2009 78 Figure 45: Drivers of buyer power in the generics market in Canada, 2009 80 Figure 46: Drivers of supplier power in the generics market in Canada, 2009 81 Figure 47: Factors influencing the likelihood of new entrants in the generics market in Canada, 2009 82 Figure 48: Factors influencing the threat of substitutes in the generics market in Canada, 2009 84 Figure 49: Drivers of degree of rivalry in the generics market in Canada, 2009 85 Figure 50: Canada generics market value forecast: $ billion, 2009–14 86 Figure 51: China generics market value: $ billion, 2005–09 90 Figure 52: China generics market segmentation I:% share, by value, 2009 91 Figure 53: China generics market segmentation II: % share, by value, 2009 92 Figure 54: Forces driving competition in the generics market in China, 2009 93 Figure 55: Drivers of buyer power in the generics market in China, 2009 95 Figure 56: Drivers of supplier power in the generics market in China, 2009 96 Figure 57: Factors influencing the likelihood of new entrants in the generics market in China, 2009 97 Figure 58: Factors influencing the threat of substitutes in the generics market in China, 2009 99 Figure 59: Drivers of degree of rivalry in the generics market in China, 2009 100 Figure 60: France generics market value: $ billion, 2005–09 104 Figure 61: France generics market segmentation I:% share, by value, 2009 105 Figure 62: France generics market segmentation II: % share, by value, 2009 106 Figure 63: Forces driving competition in the generics market in France, 2009 107 Figure 64: Drivers of buyer power in the generics market in France, 2009 109 Figure 65: Drivers of supplier power in the generics market in France, 2009 110 Figure 66: Factors influencing the likelihood of new entrants in the generics market in France, 2009 111 Figure 67: Factors influencing the threat of substitutes in the generics market in France, 2009 113 Figure 68: Drivers of degree of rivalry in the generics market in France, 2009 114 Figure 69: France generics market value forecast: $ billion, 2009–14 115 Figure 70: Germany generics market value: $ billion, 2005–09 119 Figure 71: Germany generics market segmentation I:% share, by value, 2009 120 Figure 72: Germany generics market segmentation II: % share, by value, 2009 121 Figure 73: Forces driving competition in the generics market in Germany, 2009 122 Figure 74: Drivers of buyer power in the generics market in Germany, 2009 124 Figure 75: Drivers of supplier power in the generics market in Germany, 2009 125 Figure 76: Factors influencing the likelihood of new entrants in the generics market in Germany, 2009 126 Figure 77: Factors influencing the threat of substitutes in the generics market in Germany, 2009 128 Figure 78: Drivers of degree of rivalry in the generics market in Germany, 2009 129 Figure 79: Germany generics market value forecast: $ billion, 2009–14 130 Figure 80: Italy generics market value: $ million, 2005–09 134 Figure 81: Italy generics market segmentation I:% share, by value, 2009 135 Figure 82: Italy generics market segmentation II: % share, by value, 2009 136 Figure 83: Forces driving competition in the generics market in Italy, 2009 137 Figure 84: Drivers of buyer power in the generics market in Italy, 2009 139 Figure 85: Drivers of supplier power in the generics market in Italy, 2009 140 Figure 86: Factors influencing the likelihood of new entrants in the generics market in Italy, 2009 141 Figure 87: Factors influencing the threat of substitutes in the generics market in Italy, 2009 143 Figure 88: Drivers of degree of rivalry in the generics market in Italy, 2009 144 Figure 89: Italy generics market value forecast: $ million, 2009–14 145 Figure 90: Japan generics market value: $ billion, 2005–09 149 Figure 91: Japan generics market segmentation I:% share, by value, 2009 150 Figure 92: Japan generics market segmentation II: % share, by value, 2009 151 Figure 93: Forces driving competition in the generics market in Japan, 2009 152 Figure 94: Drivers of buyer power in the generics market in Japan, 2009 154 Figure 95: Drivers of supplier power in the generics market in Japan, 2009 155 Figure 96: Factors influencing the likelihood of new entrants in the generics market in Japan, 2009 156 Figure 97: Factors influencing the threat of substitutes in the generics market in Japan, 2009 158 Figure 98: Drivers of degree of rivalry in the generics market in Japan, 2009 159 Figure 99: Japan generics market value forecast: $ billion, 2009–14 160 Figure 100: Netherlands generics market value: $ million, 2005–09 164 Figure 101: Netherlands generics market segmentation I:% share, by value, 2009 165 Figure 102: Netherlands generics market segmentation II: % share, by value, 2009 166 Figure 103: Forces driving competition in the generics market in the Netherlands, 2009 167 Figure 104: Drivers of buyer power in the generics market in the Netherlands, 2009 169 Figure 105: Drivers of supplier power in the generics market in the Netherlands, 2009 170 Figure 106: Factors influencing the likelihood of new entrants in the generics market in the Netherlands, 2009 171 Figure 107: Factors influencing the threat of substitutes in the generics market in the Netherlands, 2009 173 Figure 108: Drivers of degree of rivalry in the generics market in the Netherlands, 2009 174 Figure 109: Netherlands generics market value forecast: $ million, 2009–14 175 Figure 110: Spain generics market value: $ billion, 2005–09 179 Figure 111: Spain generics market segmentation I:% share, by value, 2009 180 Figure 112: Spain generics market segmentation II: % share, by value, 2009 181 Figure 113: Forces driving competition in the generics market in Spain, 2009 182 Figure 114: Drivers of buyer power in the generics market in Spain, 2009 184 Figure 115: Drivers of supplier power in the generics market in Spain, 2009 185 Figure 116: Factors influencing the likelihood of new entrants in the generics market in Spain, 2009 186 Figure 117: Factors influencing the threat of substitutes in the generics market in Spain, 2009 188 Figure 118: Drivers of degree of rivalry in the generics market in Spain, 2009 189 Figure 119: Spain generics market value forecast: $ billion, 2009–14 190 Figure 120: United Kingdom generics market value: $ billion, 2005–09 194 Figure 121: United Kingdom generics market segmentation I:% share, by value, 2009 195 Figure 122: United Kingdom generics market segmentation II: % share, by value, 2009 196 Figure 123: Forces driving competition in the generics market in the United Kingdom, 2009 197 Figure 124: Drivers of buyer power in the generics market in the United Kingdom, 2009 199 Figure 125: Drivers of supplier power in the generics market in the United Kingdom, 2009 200 Figure 126: Factors influencing the likelihood of new entrants in the generics market in the United Kingdom, 2009 201 Figure 127: Factors influencing the threat of substitutes in the generics market in the United Kingdom, 2009 203 Figure 128: Drivers of degree of rivalry in the generics market in the United Kingdom, 2009 204 Figure 129: United Kingdom generics market value forecast: $ billion, 2009–14 205 Figure 130: United States generics market value: $ billion, 2005–09 209 Figure 131: United States generics market segmentation I:% share, by value, 2009 210 Figure 132: United States generics market segmentation II: % share, by value, 2009 211 Figure 133: Forces driving competition in the generics market in the United States, 2009 212 Figure 134: Drivers of buyer power in the generics market in the United States, 2009 214 Figure 135: Drivers of supplier power in the generics market in the United States, 2009 215 Figure 136: Factors influencing the likelihood of new entrants in the generics market in the United States, 2009 216 Figure 137: Factors influencing the threat of substitutes in the generics market in the United States, 2009 218 Figure 138: Drivers of degree of rivalry in the generics market in the United States, 2009 219 Figure 139: United States generics market value forecast: $ billion, 2009–14 220 Figure 140: Bayer AG: revenues & profitability 227 Figure 141: Bayer AG: assets & liabilities 228 Figure 142: Mylan Laboratories Inc.: revenues & profitability 231 Figure 143: Mylan Laboratories Inc.: assets & liabilities 232 Figure 144: Novartis AG: revenues & profitability 235 Figure 145: Novartis AG: assets & liabilities 236 Figure 146: Teva Pharmaceutical Industries: revenues & profitability 240 Figure 147: Teva Pharmaceutical Industries: assets & liabilities 241 [Inhaltsverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
